What the Doctor Ordered

摘要

Flip through regulatory filings for Onyx Pharmaceuticals and you'll learn that it develops "innovative therapies targeting the molecular mechanisms that cause cancer." The tiny Richmond, Calif, biotech hasn't made a dime selling drugs, and red ink is all that lies immediately in the forecast for its bottom line. Still, its proposed drug to treat kidney, liver and other cancers―by blocking certain biochemical signals controlling tumor cell division and the formation of related blood vessels―looks promising. In the past year Onyx shares have rocketed from $7 to a 52-week high of $38.